Clinical Efficacy and Safety of Injection of Stromal Vascular Fraction Derived from Autologous Adipose Tissues in Systemic Sclerosis Patients with Hand Disability: A Proof-Of-Concept Trial.
Youngjae ParkYoon Jae LeeJung Hee KohJennifer LeeHong-Ki MinMoon Young KimKi Joo KimSu Jin LeeJong Won RhieWan-Uk KimSung-Hwan ParkSuk-Ho MoonSeung-Ki KwokPublished in: Journal of clinical medicine (2020)
Injection of SVF derived from autologous adipose tissues is tolerable, and shows clinical efficacy in SSc patients.
Keyphrases
- systemic sclerosis
- bone marrow
- interstitial lung disease
- end stage renal disease
- gene expression
- adipose tissue
- newly diagnosed
- ejection fraction
- chronic kidney disease
- multiple sclerosis
- cell therapy
- insulin resistance
- clinical trial
- ultrasound guided
- prognostic factors
- peritoneal dialysis
- randomized controlled trial
- type diabetes
- rheumatoid arthritis
- patient reported outcomes
- phase iii
- skeletal muscle
- phase ii
- open label